Treatment and Treatment Outcomes of Advanced NSCLC Patients in Routine Clinical Care: Results of the Retrospective LUCEOR Study.

6058 Background: Although NSCLC is the most common type of lung cancer, published data on both treatment patterns and outcomes in routine clinical care are scarce. Collecting this data systematically across countries will help to understand, compare and improve patient care. Methods: 1,490 patient charts were reviewed retrospectively from 40 sites in Australia, Belgium, Canada, France, Germany, Italy, Sweden, Turkey, the Netherlands and the UK, 1436 of those evaluable. Patients deceased before April 2010 were eligible if ≥18 years, diagnosed with advanced stage IIIb/IV NSCLC and had received active 1st line anti-cancer treatment. Demographic data, disease and, treatment history and resource use were collected from start of first line treatment until death. Results: Mean age at NSCLC diagnosis was 64 years [SD=10.6], 67% of patients had stage IV disease at diagnosis and 66% were male. Confirmed tumor histology was adenocarcinoma in 50% of patients, squamous and large cell carcinoma in 23% and 14%, respectively. Tumour histology was not available in 13% of patients. Mean number of treatment lines was 1.7 [range 1-8]. Biomarker analysis was performed in 19% of patients (of those 26% and 13% tested for EGFR and KRAS mutation, respectively) within less than one month of diagnosis. 1st line therapy included mainly platinum doublets (86%, mostly carboplatine/gemcitabine [23%]), 2nd line included erlotinib (35%) and pemetrexed (18%), and 3rd line included erlotinib (38%) and docetaxel (17%). Most treated patients had ECOG performance status of 1. Stable disease (based on RECIST) was highest during 1st line therapy with 30%. Median PFS from start of 1st line treatment was 3.8 months [SD=7.1], with a median OS of 7.1 months [SD=11.6]. Conclusions: The majority of patients were diagnosed with an adenocarcinoma and a number of patients were tested for EGFR or KRAS mutation. Overall treatment outcomes observed in routine care seem lower than those observed in clinical trials. Also current therapeutic options for NSCLC seem to provide limited clinical benefit, underpinning the need for new treatment alternatives to prolong PFS and OS.